

Initial baseline characteristics between 93 patients completed visits at M12 and 163 patients lost to follow up

CHARACTERISTICS	Patients with data (N=93)			Patients lost to follow-up (N=163)			P
	N	Number (%)	Mean (SD)	N	Number (%)	Mean (SD)	
DEMOGRAPHIC							
Age (y)	93	—	52.4 (11.7)	163	—	49.8 (11.3)	0.08
Sex (female)		74 (79.6)	—		120 (73.6)	—	0.29
PAIN-RELATED							
Pain type							
Fibromyalgia	93	39 (41.9)	—	163	76 (46.6)	—	0.47
Peripheral neuropathic pain		19 (20.4)	—		53 (32.5)	—	0.04
Central neuropathic pain		11 (11.8)	—		8 (4.9)	—	0.04
Complex Regional Pain Syndrome		15 (16.1)	—		14 (8.6)	—	0.07
Back pain, Sciatica, Cruralgia, Neuralgia, Pelvic pain, Gonarthrosis		8 (8.6)	—		8 (4.9)	—	0.24
Polyarthrititis, Spondylitis		0	—		1 (0.6)	—	0.45
Others		1 (1.1)	—		3 (1.8)	—	0.64
Pain status							
Score DN4 ^a ≥ 4		67 (83.8)	—		119 (81.5)	—	0.67
Average pain intensity	85	—	6.7 (1.7)	155	—	6.8 (1.8)	0.60
<i>Average pain < 3</i>		2 (2.4)	—		4 (2.6)	—	0.89
<i>Average pain [3 – 6]</i>		34 (40.0)	—		57 (36.8)	—	
<i>Average pain ≥ 7</i>		49 (57.7)	—		94 (60.7)	—	
Number of painful peaks (median [IQR])	48	—	4 [2.5;6.3]	86	—	4 [3;7]	0.55
Maximal pain intensity	89	—	8.0 (1.6)	155	—	8.3 (1.6)	0.08
<i>Maximal pain < 3</i>		2 (2.3)	—		1 (0.7)	—	0.41
<i>Maximal pain [3 – 6]</i>		10 (11.2)	—		13 (8.4)	—	
<i>Maximal pain ≥ 7</i>		77 (86.5)	—		141 (91.0)	—	
KETAMINE							
Patient profile (naïf)	93	48 (51.6)	—	163	78 (47.9)	—	0.56
Administration (after baseline)							
Intravenous route	93	86 (92.5)	—	163	141 (86.5)	—	0.15
Cumulative dose (mg) ^b (median [IQR])	86	—	245 [157.5; 268.5]	141	—	210 [105; 269.5]	<0.001

Cumulative dose ≤ 222 (mg)	36 (41.9)	—	99 (70.2)	—	<0.001		
Cumulative dose > 222 (mg)	50 (58.1)	—	42 (29.8)	—			
Cumulative duration (d) ^b (median [IQR])	—	3 [3;5]	—	4 [3;5]	0.27		
≤3 days	41 (47.7)	—	78 (55.3)	—	0.28		
≥4 days	45 (52.3)	—	63 (44.7)	—			
EMOTIONAL ASPECTS							
HAD, anxiety symptoms score	86	—	10.7 (4.2)	155	—	10.0 (4.5)	0.20
Score ≤7	23 (26.7)	—	50 (32.3)	—	0.69		
Score [8-10]	20 (23.3)	—	37 (23.9)	—			
Score ≥11	43 (50.0)	—	68 (43.9)	—			
HAD, depression symptoms score	85	—	9.1 (3.9)	152	—	9.2 (4.8)	0.07
Score ≤7	34 (40.0)	—	61 (40.1)	—	0.36		
Score [8-10]	23 (27.1)	—	30 (19.7)	—			
Score ≥11	28 (32.9)	—	61 (40.1)	—			
QUALITY OF LIFE							
SF12 – Physical score	74	—	30.8 (8.5)	145	—	29.7 (7.9)	0.69
SF12 – Mental score	—	—	39.2 (9.3)	—	—	38.2 (11.4)	0.33
CONCOMITANT DRUGS							
Treatment category							
Paracetamol/NSAIDs	93	44 (47.3)	—	152	60 (39.5)	—	0.23
Opioids step 2 ^a , nefopam	42 (45.2)	—	67 (44.1)	—	0.87		
Opioids step 3 ^b	14 (15.1)	—	21 (13.8)	—	0.79		
Antidepressants	60 (64.5)	—	86 (56.6)	—	0.18		
Antiepileptics	28 (30.1)	—	40 (26.3)	—	0.52		
Adjuvants	23 (24.7)	—	28 (18.4)	—	0.24		
Hypnotics/Sedatives	15 (16.1)	—	22 (14.5)	—	0.73		
Anxiolytics	27 (29.0)	—	32 (21.1)	—	0.16		
Antipsychotics	9 (9.7)	—	4 (2.6)	—	0.02		
None	5 (5.4)	—	14 (9.2)	—	0.28		


Supplemental Digital Content 2

Pain evolution with or without the LOCF method


ANALYSES			With LOCF method		Without imputation analysis	
TIMEPOINT	ALL PATIENTS N=256 (imputation)		SAMPLE TO LAST CONTACT N=256 (imput + 2 pts)		SAMPLE WITH DATA N=220 (sans imput + 2pts)	
	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)
Baseline	256	6.7 (1.8)	240	6.8 (1.8)	240	6.8 (1.8)
W1	256	5.7 (1.9)*	256	5.7 (1.9)*	218	5.5 (1.8)*
M1	256	5.8 (2.0)*	221	5.6 (1.9)*	172	5.6 (1.9)*
M2	256	5.8 (2.0)*	207	5.6 (1.9)*	137	5.6 (1.9)*
M3	256	5.7 (2.1)*	187	5.6 (2.0)*	110	5.7 (2.1)*
M4	256	5.8 (2.1)*	177	5.7 (2.1)*	95	5.8 (2.1)*
M5	256	5.8 (2.1)*	173	5.6 (2.1)*	84	5.8 (2.2)*
M6	256	5.8 (2.1)*	167	5.7 (2.0)*	85	6.1 (2.1)*
M7	256	5.8 (2.1)*	162	5.8 (2.0)*	93	6.0 (2.2)*
M8	256	5.8 (2.1)*	159	5.7 (2.0)*	108	5.8 (2.1)*
M9	256	5.8 (2.1)*	154	5.6 (1.9)*	126	5.6 (1.9)*
M10	256	5.9 (2.1)*	148	5.6 (1.9)*	136	5.7 (1.9)*
M11	256	5.9 (2.1)*	137	5.7 (2.0)*	134	5.7 (2.0)*
M12	256	5.9 (2.1)*	93	5.7 (1.8)*	93	5.7 (1.8)*
TRAJECTORIES	N	%	N	%	N	%
T1	44	16.9	38	16.0	28	14.4
T2	107	41.3	83	35.3	85	41.9
T3	105	41.8	119	48.7	93	43.7

SD: Standard Deviation; M: month(s); W: week, T1: trajectory1, T2: trajectory 2; T3: trajectory 3; *p<0.001(comparison with baseline);

Supplemental digital content 3. Pharmacological treatments during the year of follow-up. NSAIDs: NonSteroidal Anti-Inflammatory Drugs



Supplemental digital content 4. No-pharmacological approaches. TENS: Transcutaneous Electrical Nerve Stimulation



Initial baseline characteristics of 220 patients stratified by trajectory without imputation analysis

CHARACTERISTICS	TRAJECTORY 1 (14.4%)			TRAJECTORY 2 (41.9%)			TRAJECTORY 3 (43.7%)			P
	N	Number (%)	Mean (SD)	N	Number (%)	Mean (SD)	N	Number (%)	Mean (SD)	
DEMOGRAPHICS										
Age (y)	31	—	47.8 (9.1)	89	—	53.1 (11.6)	100	—	50.7 (12.5)	0.07
Sex (female)		20 (64.5)	—		71 (79.8)	—		81 (81.0)	—	0.14
PAIN-RELATED										
Pain type										
Fibromyalgia	31	11 (35.5)	—	89	39 (43.8)	—	100	52 (52.0)	—	0.23
Peripheral neuropathic pain		9 (29.0)	—		20 (22.5)	—		28 (28.0)	—	0.63
Central neuropathic pain		0 (0)	—		11 (12.4)	—		6 (6.0)	—	0.06
Complex Regional Pain Syndrome		6 (19.4)	—		10 (11.2)	—		9 (9.0)	—	0.28
Back pain, Sciatica, Cruralgia, Neuralgia, Pelvic pain, Gonarthrosis		4 (12.9)	—		7 (7.9)	—		4 (4.0)	—	0.20
Polyarthrititis, Spondylitis		0 (0)	—		0 (0)	—		1 (1.0)	—	0.55
Others		1 (3.2)	—		2 (2.3)	—		0 (0)	—	0.26
Pain status										
Score DN4 ^a ≥ 4	28	21 (75.0)	—	76	61 (80.3)	—	91	78 (85.7)	—	0.38
Average pain intensity	28	—	5.3 (1.6)	85	—	6.3 (1.6)	93	—	7.6 (1.3)	<0.001
Average pain < 3	28	2 (7.1)	—	85	—	2 (2.4)	93	0 (0)	—	<0.001
Average pain [3 – 6]		20 (71.4)	—		42 (49.4)	—		20 (21.5)	—	
Average pain ≥ 7		6 (21.4)	—		41 (48.2)	—		73 (78.5)	—	
Number of painful peaks (median [IQR])	15	—	3 [2.5]	47	—	3.5 [2;5]	53	—	4 [3; 8]	0.07
Maximal pain intensity	29	—	7.1 (1.7)	87	—	7.9 (1.4)	94	—	8.7 (1.4)	<0.001
Maximal pain < 3		0 (0)	—		1 (1.2)	—		1 (1.1)	—	0.009
Maximal pain [3 – 6]		8 (27.6)	—		9 (10.3)	—		4 (4.3)	—	
Maximal pain ≥ 7		21 (72.4)	—		77 (88.5)	—		89 (94.7)	—	
KETAMINE										
Patient profile (naive)	31	16 (51.6)	—	89	42 (47.2)	—	100	57 (57.0)	—	0.40
Administration (after baseline)										
Intravenous route	31	28 (90.3)	—	89	81 (91.0)	—	100	84 (84.0)	—	0.33

Cumulative dose (mg) ^b (median [IQR])	28	—	222 [136.5; 269.5]	81	—	245 [136.5; 269.5]	84	—	189 [100; 269.5]	0.08
Cumulative dose ≤ 222 (mg)		17 (60.7)	—		37 (45.7)	—		57 (67.9)	—	0.02
Cumulative dose > 222 (mg)		11 (39.3)	—		44 (54.3)	—		27 (32.1)	—	
Cumulative duration (d) ^b (median [IQR])	28	—	4 [3; 5]	81	—	4 [3; 5]	84	3 [3;5]	—	0.89
≤3 days		13 (46.4)	—		40 (49.4)	—		43 (51.2)	—	0.92
≥4 days		15 (53.6)	—		41 (50.6)	—		41 (48.8)	—	
EMOTIONAL ASPECTS										
HAD, anxiety symptoms score	29	—	7.8 (4.7)	83	—	10.5 (4.1)	95	—	11.0 (4.3)	0.006
Score ≤7		14 (48.3)	—		23 (27.7)	—		21 (22.1)	—	0.10
Score [8-10]		5 (17.2)	—		22 (26.5)	—		25 (26.3)	—	
Score ≥11		10 (34.5)	—		28 (45.8)	—		49 (51.6)	—	
HAD, depression symptoms score	29	—	7.3 (4.9)	80	—	9.3 (4.1)	96	—	9.8 (4.4)	0.02
Score ≤7		17 (58.6)	—		30 (37.5)	—		33 (34.4)	—	0.11
Score [8-10]		5 (17.2)	—		23 (28.8)	—		21 (21.9)	—	
Score ≥11		7 (24.1)	—		27 (33.8)	—		42 (43.8)	—	
QUALITY OF LIFE										
SF12 – Physical score	26	—	33.7 (8.2)	72	—	31.3 (7.1)	90	—	28.0 (8.5)	0.003
SF12 – Mental score		—	40.0 (12.2)		—	37.9 (9.2)		—	38.2 (11.5)	0.83
CONCOMITANT DRUGS										
Number of treatments	31	—	2.2 (1.8)	89	—	3.3 (1.7)	100	—	2.9 (1.8)	0.01
Treatment category										
Paracetamol/NSAIDs	31	11 (35.5)	—	89	38 (42.7)	—	100	46 (46.0)	—	0.58
Opioids step 2 ^c , nefopam		7 (22.6)	—		50 (56.2)	—		43 (43.0)	—	0.004
Opioids step I3 ^d		5 (16.1)	—		12 (13.5)	—		12 (12.0)	—	0.83
Antidepressants		21 (67.7)	—		58 (65.2)	—		61 (61.0)	—	0.74
Antiepileptics		6 (19.4)	—		26 (29.2)	—		28 (28.0)	—	0.56
Adjuvants		5 (16.1)	—		22 (24.7)	—		21 (21.0)	—	0.59
Hypnotics/Sedatives		5 (16.1)	—		12 (13.5)	—		15 (15.0)	—	0.96
Anxiolytics		5 (16.1)	—		31 (34.8)	—		19 (19.0)	—	0.02
Antipsychotics		1 (3.2)	—		6 (6.7)	—		6 (6.0)	—	0.78
None		6 (19.4)	—		3 (3.4)	—		9 (9.0)	—	0.02

Initial baseline characteristics of 220 patients stratified by trajectory without imputation analysis

CHARACTERISTICS	TRAJECTORY 1 (14.4%)			TRAJECTORY 2 (41.9%)			TRAJECTORY 3 (43.7%)			P
	N	Number (%)	Mean (SD)	N	Number (%)	Mean (SD)	N	Number (%)	Mean (SD)	
DEMOGRAPHICS										
Age (y)	31	—	47.8 (9.1)	89	—	53.1 (11.6)	100	—	50.7 (12.5)	0.07
Sex (female)		20 (64.5)	—		71 (79.8)	—		81 (81.0)	—	0.14
PAIN-RELATED										
Pain type										
Fibromyalgia	31	11 (35.5)	—	89	39 (43.8)	—	100	52 (52.0)	—	0.23
Peripheral neuropathic pain		9 (29.0)	—		20 (22.5)	—		28 (28.0)	—	0.63
Central neuropathic pain		0 (0)	—		11 (12.4)	—		6 (6.0)	—	0.06
Complex Regional Pain Syndrome		6 (19.4)	—		10 (11.2)	—		9 (9.0)	—	0.28
Back pain, Sciatica, Cruralgia, Neuralgia, Pelvic pain, Gonarthrosis		4 (12.9)	—		7 (7.9)	—		4 (4.0)	—	0.20
Polyarthritis, Spondylitis		0 (0)	—		0 (0)	—		1 (1.0)	—	0.55
Others		1 (3.2)	—		2 (2.3)	—		0 (0)	—	0.26
Pain status										
Score DN4 ^a ≥ 4	28	21 (75.0)	—	76	61 (80.3)	—	91	78 (85.7)	—	0.38
Average pain intensity	28	—	5.3 (1.6)	85	—	6.3 (1.6)	93	—	7.6 (1.3)	<0.001
Average pain < 3	28	2 (7.1)	—	85	—	2 (2.4)	93	0 (0)	—	<0.001
Average pain [3 – 6]		20 (71.4)	—		42 (49.4)	—		20 (21.5)	—	
Average pain ≥ 7		6 (21.4)	—		41 (48.2)	—		73 (78.5)	—	
Number of painful peaks (median [IQR])	15	—	3 [2.5]	47	—	3.5 [2;5]	53	—	4 [3; 8]	0.07
Maximal pain intensity	29	—	7.1 (1.7)	87	—	7.9 (1.4)	94	—	8.7 (1.4)	<0.001
Maximal pain < 3		0 (0)	—		1 (1.2)	—		1 (1.1)	—	0.009
Maximal pain [3 – 6]		8 (27.6)	—		9 (10.3)	—		4 (4.3)	—	
Maximal pain ≥ 7		21 (72.4)	—		77 (88.5)	—		89 (94.7)	—	
KETAMINE										
Patient profile (naive)	31	16 (51.6)	—	89	42 (47.2)	—	100	57 (57.0)	—	0.40
Administration (after baseline)										
Intravenous route	31	28 (90.3)	—	89	81 (91.0)	—	100	84 (84.0)	—	0.33

Cumulative dose (mg) ^b (median [IQR])	28	—	222 [136.5; 269.5]	81	—	245 [136.5; 269.5]	84	—	189 [100; 269.5]	0.08
Cumulative dose ≤ 222 (mg)		17 (60.7)	—		37 (45.7)	—		57 (67.9)	—	0.02
Cumulative dose > 222 (mg)		11 (39.3)	—		44 (54.3)	—		27 (32.1)	—	
Cumulative duration (d) ^b (median [IQR])	28	—	4 [3; 5]	81	—	4 [3; 5]	84	3 [3;5]	—	0.89
≤3 days		13 (46.4)	—		40 (49.4)	—		43 (51.2)	—	0.92
≥4 days		15 (53.6)	—		41 (50.6)	—		41 (48.8)	—	
EMOTIONAL ASPECTS										
HAD, anxiety symptoms score	29	—	7.8 (4.7)	83	—	10.5 (4.1)	95	—	11.0 (4.3)	0.006
Score ≤7		14 (48.3)	—		23 (27.7)	—		21 (22.1)	—	0.10
Score [8-10]		5 (17.2)	—		22 (26.5)	—		25 (26.3)	—	
Score ≥11		10 (34.5)	—		28 (45.8)	—		49 (51.6)	—	
HAD, depression symptoms score	29	—	7.3 (4.9)	80	—	9.3 (4.1)	96	—	9.8 (4.4)	0.02
Score ≤7		17 (58.6)	—		30 (37.5)	—		33 (34.4)	—	0.11
Score [8-10]		5 (17.2)	—		23 (28.8)	—		21 (21.9)	—	
Score ≥11		7 (24.1)	—		27 (33.8)	—		42 (43.8)	—	
QUALITY OF LIFE										
SF12 – Physical score	26	—	33.7 (8.2)	72	—	31.3 (7.1)	90	—	28.0 (8.5)	0.003
SF12 – Mental score		—	40.0 (12.2)		—	37.9 (9.2)		—	38.2 (11.5)	0.83
CONCOMITANT DRUGS										
Number of treatments	31	—	2.2 (1.8)	89	—	3.3 (1.7)	100	—	2.9 (1.8)	0.01
Treatment category										
Paracetamol/NSAIDs	31	11 (35.5)	—	89	38 (42.7)	—	100	46 (46.0)	—	0.58
Opioids step 2 ^c , nefopam		7 (22.6)	—		50 (56.2)	—		43 (43.0)	—	0.004
Opioids step I3 ^d		5 (16.1)	—		12 (13.5)	—		12 (12.0)	—	0.83
Antidepressants		21 (67.7)	—		58 (65.2)	—		61 (61.0)	—	0.74
Antiepileptics		6 (19.4)	—		26 (29.2)	—		28 (28.0)	—	0.56
Adjuvants		5 (16.1)	—		22 (24.7)	—		21 (21.0)	—	0.59
Hypnotics/Sedatives		5 (16.1)	—		12 (13.5)	—		15 (15.0)	—	0.96
Anxiolytics		5 (16.1)	—		31 (34.8)	—		19 (19.0)	—	0.02
Antipsychotics		1 (3.2)	—		6 (6.7)	—		6 (6.0)	—	0.78
None		6 (19.4)	—		3 (3.4)	—		9 (9.0)	—	0.02

Initial baseline characteristics of 256 patients stratified by trajectory with LOCF method

CHARACTERISTICS	TRAJECTORY 1 (16.9%)			TRAJECTORY 2 (41.3%)			TRAJECTORY 3 (41.8%)			P
	N	Number (%)	Mean (SD)	N	Number (%)	Mean (SD)	N	Number (%)	Mean (SD)	
DEMOGRAPHICS										
Age (y)	44	—	47.7 (10.9)	107	—	52.0 (12.0)	105	—	50.6 (11.1)	0.15
Sex (female)		25 (56.8)	—		87 (81.3)	—		82 (78.1)	—	0.005
PAIN-RELATED										
Pain type										
Fibromyalgia	44	12 (27.3)	—	107	49 (45.8)	—	105	54 (51.4)	—	0.025
Peripheral neuropathic pain		15 (34.1)	—		27 (25.2)	—		30 (28.6)	—	0.54
Central neuropathic pain		1 (2.3)	—		12 (11.2)	—		6 (5.7)	—	0.11
Complex Regional Pain Syndrome		9 (20.5)	—		11 (10.3)	—		9 (8.6)	—	0.10
Back pain, Sciatica, Cruralgia, Neuralgia, Pelvic pain, Gonarthrosis		6 (13.6)	—		6 (5.6)	—		4 (3.8)	—	0.07
Polyarthritis, Spondylitis		0	—		0	—		1 (1.0)	—	0.49
Others		1 (2.3)	—		2 (1.9)	—		10 (1.0)	—	0.79
Pain status										
Score DN4 ^a ≥ 4	39	27 (69.2)	—	90	74 (82.2)	—	97	85 (87.6)	—	0.039
Average pain intensity	44	—	5.1 (2.0)	107	—	6.4 (1.6)	105	—	7.6 (1.4)	<0.001
<i>Average pain < 3</i>	40	4 (10.0)	—	101	—	2 (2.0)	99	0	—	<0.001
<i>Average pain [3 – 6]</i>		26 (65.0)	—		48 (47.5)	—		17 (17.2)	—	
<i>Average pain ≥ 7</i>		10 (25.0)	—		51 (50.5)	—		82 (82.8)	—	
Number of painful peaks (median [IQR])	19	—	3 [2.5; 5]	56	—	3.5 [2; 5]	59	—	4.5 [3; 10]	0.03
Maximal pain intensity	41	—	7.2 (2.0)	102	—	8.0 (1.3)	101	—	8.7 (1.4)	<0.001
<i>Maximal pain < 3</i>		1 (2.4)	—		1 (1.0)	—		1 (1.0)	—	0.004
<i>Maximal pain [3 – 6]</i>		10 (24.4)	—		9 (8.8)	—		4 (4.0)	—	
<i>Maximal pain ≥ 7</i>		30 (73.2)	—		92 (90.2)	—		96 (95.1)	—	
KETAMINE										
Patient profile (naive)	44	22 (50.0)	—	107	56 (52.3)	—	105	48 (45.7)	—	0.62

Administration (after baseline)										
Intravenous route	44	41 (93.2)	—	107	97 (90.7)	—	105	89 (84.8)	—	0.23
Cumulative dose (mg) ^b (median [IQR])	44	—	222 [105; 269.5]	107	—	245 [140; 269.5]	105	—	168 [100; 222]	
Cumulative dose ≤ 222 (mg)		24 (58.5)	—		43 (44.3)	—		68 (76.4)	—	<0.001
Cumulative dose > 222 (mg)		17 (41.5)	—		54 (55.7)	—		21 (23.6)	—	
Cumulative duration (d) ^b (median [IQR])	41	—	4 [3;5]	97	—	4 [3; 5]	89	—	3 [3;5]	0.62
≤3 days		20 (48.8)	—		48 (49.5)	—		51 (57.3)	—	0.52
≥4 days		21 (51.2)	—		49 (50.5)	—		38 (42.7)	—	
EMOTIONAL ASPECTS										
HAD, anxiety symptoms score	41	—	7.7 (4.3)	102	—	10.5 (4.2)	98	—	11.0 (4.3)	<0.001
Score ≤7		20 (48.8)	—		30 (29.4)	—		23 (23.5)	—	0.016
Score [8-10]		9 (22.0)	—		28 (27.5)	—		20 (20.4)	—	
Score ≥11		12 (29.3)	—		44 (43.1)	—		55 (56.1)	—	
HAD, depression symptoms score	41	—	7.3 (4.9)	98	—	9.5 (4.1)	98	—	9.6 (4.6)	0.02
Score ≤7		23 (56.1)	—		37 (37.8)	—		35 (35.7)	—	0.184
Score [8-10]		7 (17.1)	—		25 (25.5)	—		21 (21.4)	—	
Score ≥11		11 (26.8)	—		36 (36.7)	—		42 (42.9)	—	
QUALITY OF LIFE										
SF12 – Physical score	37	—	34.3 (8.5)	90	—	30.3 (7.0)	92	—	28.1 (8.4)	0.002
SF12 – Mental score		—	41.3 (11.9)		—	37.8 (9.4)		—	38.1 (11.3)	0.36
CONCOMITANT DRUGS										
Number of treatments	40	—	2.6 (2.0)	105	—	3.2 (1.7)	100	—	2.9 (1.7)	0.09
Treatment category										
Paracetamol/NSAIDs	40	16 (40.0)	—	105	46 (43.8)	—	100	42 (42.0)	—	0.91
Opioids step2 ^c , nefopam		12 (30.0)	—		55 (52.4)	—		42 (42.0)	—	0.043
Opioids step 3 ^d		8 (20.0)	—		16 (15.2)	—		11 (11.0)	—	0.36
Antidepressants		23 (57.5)	—		65 (61.9)	—		58 (58.0)	—	0.81
Antiepileptics		12 (30.0)	—		32 (30.5)	—		27 (27.0)	—	0.85
Adjuvants		6 (15.0)	—		25 (23.8)	—		20 (20.0)	—	0.49
Hypnotics/Sedatives		7 (17.5)	—		16 (15.2)	—		14 (14.0)	—	0.87
Anxiolytics		7 (17.5)	—		33 (31.4)	—		19 (19.0)	—	0.065
Antipsychotics		3 (7.5)	—		5 (4.8)	—		5 (5.0)	—	0.79
None		7 (17.5)	—		5 (4.8)	—		7 (7.0)	—	0.035

Initial baseline characteristics of 220 patients stratified by trajectory without imputation analysis

CHARACTERISTICS	TRAJECTORY 1 (14.4%)			TRAJECTORY 2 (41.9%)			TRAJECTORY 3 (43.7%)			P
	N	Number (%)	Mean (SD)	N	Number (%)	Mean (SD)	N	Number (%)	Mean (SD)	
DEMOGRAPHICS										
Age (y)	31	—	47.8 (9.1)	89	—	53.1 (11.6)	100	—	50.7 (12.5)	0.07
Sex (female)		20 (64.5)	—		71 (79.8)	—		81 (81.0)	—	0.14
PAIN-RELATED										
Pain type										
Fibromyalgia	31	11 (35.5)	—	89	39 (43.8)	—	100	52 (52.0)	—	0.23
Peripheral neuropathic pain		9 (29.0)	—		20 (22.5)	—		28 (28.0)	—	0.63
Central neuropathic pain		0 (0)	—		11 (12.4)	—		6 (6.0)	—	0.06
Complex Regional Pain Syndrome		6 (19.4)	—		10 (11.2)	—		9 (9.0)	—	0.28
Back pain, Sciatica, Cruralgia, Neuralgia, Pelvic pain, Gonarthrosis		4 (12.9)	—		7 (7.9)	—		4 (4.0)	—	0.20
Polyarthritis, Spondylitis		0 (0)	—		0 (0)	—		1 (1.0)	—	0.55
Others		1 (3.2)	—		2 (2.3)	—		0 (0)	—	0.26
Pain status										
Score DN4 ^a ≥ 4	28	21 (75.0)	—	76	61 (80.3)	—	91	78 (85.7)	—	0.38
Average pain intensity	28	—	5.3 (1.6)	85	—	6.3 (1.6)	93	—	7.6 (1.3)	<0.001
Average pain < 3	28	2 (7.1)	—	85	—	2 (2.4)	93	0 (0)	—	<0.001
Average pain [3 – 6]		20 (71.4)	—		42 (49.4)	—		20 (21.5)	—	
Average pain ≥ 7		6 (21.4)	—		41 (48.2)	—		73 (78.5)	—	
Number of painful peaks (median [IQR])	15	—	3 [2.5]	47	—	3.5 [2;5]	53	—	4 [3; 8]	0.07
Maximal pain intensity	29	—	7.1 (1.7)	87	—	7.9 (1.4)	94	—	8.7 (1.4)	<0.001
Maximal pain < 3		0 (0)	—		1 (1.2)	—		1 (1.1)	—	0.009
Maximal pain [3 – 6]		8 (27.6)	—		9 (10.3)	—		4 (4.3)	—	
Maximal pain ≥ 7		21 (72.4)	—		77 (88.5)	—		89 (94.7)	—	
KETAMINE										
Patient profile (naive)	31	16 (51.6)	—	89	42 (47.2)	—	100	57 (57.0)	—	0.40
Administration (after baseline)										
Intravenous route	31	28 (90.3)	—	89	81 (91.0)	—	100	84 (84.0)	—	0.33

Cumulative dose (mg) ^b (median [IQR])	28	—	222 [136.5; 269.5]	81	—	245 [136.5; 269.5]	84	—	189 [100; 269.5]	0.08
Cumulative dose ≤ 222 (mg)		17 (60.7)	—		37 (45.7)	—		57 (67.9)	—	0.02
Cumulative dose > 222 (mg)		11 (39.3)	—		44 (54.3)	—		27 (32.1)	—	
Cumulative duration (d) ^b (median [IQR])	28	—	4 [3; 5]	81	—	4 [3; 5]	84	3 [3;5]	—	0.89
≤3 days		13 (46.4)	—		40 (49.4)	—		43 (51.2)	—	0.92
≥4 days		15 (53.6)	—		41 (50.6)	—		41 (48.8)	—	
EMOTIONAL ASPECTS										
HAD, anxiety symptoms score	29	—	7.8 (4.7)	83	—	10.5 (4.1)	95	—	11.0 (4.3)	0.006
Score ≤7		14 (48.3)	—		23 (27.7)	—		21 (22.1)	—	0.10
Score [8-10]		5 (17.2)	—		22 (26.5)	—		25 (26.3)	—	
Score ≥11		10 (34.5)	—		28 (45.8)	—		49 (51.6)	—	
HAD, depression symptoms score	29	—	7.3 (4.9)	80	—	9.3 (4.1)	96	—	9.8 (4.4)	0.02
Score ≤7		17 (58.6)	—		30 (37.5)	—		33 (34.4)	—	0.11
Score [8-10]		5 (17.2)	—		23 (28.8)	—		21 (21.9)	—	
Score ≥11		7 (24.1)	—		27 (33.8)	—		42 (43.8)	—	
QUALITY OF LIFE										
SF12 – Physical score	26	—	33.7 (8.2)	72	—	31.3 (7.1)	90	—	28.0 (8.5)	0.003
SF12 – Mental score		—	40.0 (12.2)		—	37.9 (9.2)		—	38.2 (11.5)	0.83
CONCOMITANT DRUGS										
Number of treatments	31	—	2.2 (1.8)	89	—	3.3 (1.7)	100	—	2.9 (1.8)	0.01
Treatment category										
Paracetamol/NSAIDs	31	11 (35.5)	—	89	38 (42.7)	—	100	46 (46.0)	—	0.58
Opioids step 2 ^c , nefopam		7 (22.6)	—		50 (56.2)	—		43 (43.0)	—	0.004
Opioids step 3 ^d		5 (16.1)	—		12 (13.5)	—		12 (12.0)	—	0.83
Antidepressants		21 (67.7)	—		58 (65.2)	—		61 (61.0)	—	0.74
Antiepileptics		6 (19.4)	—		26 (29.2)	—		28 (28.0)	—	0.56
Adjuvants		5 (16.1)	—		22 (24.7)	—		21 (21.0)	—	0.59
Hypnotics/Sedatives		5 (16.1)	—		12 (13.5)	—		15 (15.0)	—	0.96
Anxiolytics		5 (16.1)	—		31 (34.8)	—		19 (19.0)	—	0.02
Antipsychotics		1 (3.2)	—		6 (6.7)	—		6 (6.0)	—	0.78
None		6 (19.4)	—		3 (3.4)	—		9 (9.0)	—	0.02